Kyntra Bio (KYNB) Free Cash Flow (2014 - 2026)
Kyntra Bio (KYNB) posted Free Cash Flow of -$13.9 million for Q1 2026, up 24.23% sequentially from -$18.3 million in Q4 2025, and down 613.76% YoY from $2.7 million in Q1 2025.
Kyntra Bio (KYNB) Free Cash Flow (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Free Cash Flow for 13 years, with the latest figure at -$13.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 613.76% year-over-year to -$13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.4 million (up 71.93% YoY) and the FY2025 annual result came in at -$4.8 million, up 96.52% from the prior year.
- Free Cash Flow rose to -$13.9 million in Q1 2026 per KYNB's latest filing, from -$18.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $12.7 million in Q2 2025 and troughed at -$111.6 million in Q2 2023.
- A 5-year average of -$36.4 million and a median of -$30.6 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow sank 910.3% in 2023, then soared 131.77% in 2025.
- Over 5 years, Free Cash Flow stood at -$49.5 million in 2022, then soared by 67.38% to -$16.2 million in 2023, then sank by 89.45% to -$30.6 million in 2024, then surged by 40.12% to -$18.3 million in 2025, then climbed by 24.23% to -$13.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$13.9 million, -$18.3 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | -3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.99 Mn |
| Jun 30, 2026 | -3.99 Mn |
| Mar 31, 2026 | -13.89 Mn |
| Mar 31, 2026 | -13.89 Mn |
| Dec 31, 2025 | -18.33 Mn |
| Dec 31, 2025 | -18.33 Mn |
| Sep 30, 2025 | -1.86 Mn |
| Sep 30, 2025 | -1.86 Mn |
| Jun 30, 2025 | 12.67 Mn |
| Jun 30, 2025 | 12.67 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | -30.61 Mn |
| Dec 31, 2024 | -30.61 Mn |
| Sep 30, 2024 | -8.46 Mn |
| Sep 30, 2024 | -8.46 Mn |
| Jun 30, 2024 | -39.88 Mn |
| Jun 30, 2024 | -39.88 Mn |
| Mar 31, 2024 | -59.32 Mn |
| Mar 31, 2024 | -59.32 Mn |